Federal contract award
75N93020F00001
THE CONTRACTOR SHALL PERFORM A PHASE I CLINICAL STUDY TO EVALUATE INFECTIVITY, SAFETY, AND IMMUNOGENICITY OF A SINGLE INTRANASAL DOSE OF THE RECOMBINANT LIVE-ATTENUATED RSV VACCINE LID/DELTAM2-2/1030S IN RSV SERONEGATIVE CHILDREN AND INFANTS.
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AJ52 — LIFE SCIENCES - APPLIED RESEARCH/EXPLORATORY DEVELOPMENT |
| Parent award / vehicle | 75N93019D00031 |
| Set-aside | Not reported |
| Pricing type | COST NO FEE |
| Obligations | $4.1M |
| Current contract value | $4.1M |
| Potential contract value / ceiling | $4.1M |
| Start date | Jun 10, 2020 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Nov 19, 2024 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 6 of 6 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Nov 19, 2024 | P00005 | $0 | OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS, VACCINES AND ANTIVIRALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS |
| Jun 3, 2024 | P00004 | $0 | OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS, VACCINES AND ANTIVIRALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS |
| Aug 29, 2023 | P00003 | $0 | OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS, VACCINES AND ANTIVIRALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS |
| Jun 29, 2022 | P00002 | $780.1K | OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS, VACCINES AND ANTIVIRALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS |
| Dec 16, 2021 | P00001 | $0 | OPERATION OF A FACILITY FOR THE STUDY OF INFECTIOUS AGENTS, VACCINES AND ANTIVIRALS IN ADULT AND PEDIATRIC HUMAN SUBJECTS |
| Jun 10, 2020 | 0 | $3.3M | THE CONTRACTOR SHALL PERFORM A PHASE I CLINICAL STUDY TO EVALUATE INFECTIVITY, SAFETY, AND IMMUNOGENICITY OF A SINGLE INTRANASAL DOSE OF THE RECOMBINANT LIVE-ATTENUATED RSV VACCINE LID/DELTAM2-2/1030S IN RSV SERONEGATIVE CHILDREN AND INFANTS. |
Research next steps
- Confirm the ordering vehicle and your eligibility or a qualified teaming route.
- Review the award scope and buyer evidence before making a bid/no-bid decision.